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A microtiter broth dilution method was employed to determine the in vitro
activity of mecillinam against 201 recent clinical isolates of anaerobic bacteria.
Both the anaerobic gram-positive and anaerobic gram-negative bacilli displayed
a wide range of minimal inhibitory concentrations of mecilhinam; most strains
were resistant to the antibiotic. The anaerobic cocci exhibited a narrower range
of minimal inhibitory concentrations than were observed with other anaerobes,
but also exhibited mecillinam resistance. As a single drug, mecillinam does not
appear to be an effective antimicrobial agent against anaerobic bacteria.
Mecillinam, a new beta-lactam antibiotic, was
first described by Lund and Tybring (4). This
antibiotic belongs to a new and novel class of
penicillins, the amidino penicillins. In general,
penicillins, whether natural or semisynthetic, are
acyl derivatives of 6-amino-penicillanic acid.
Mecillinam is a 6,8-amidinopenicillanic acid de-
rivative (4). In contrast to most penicillins,
which generally are more active against gram-
positive organisms, mecillinam possesses a re-
markably high activity against many members
of the Enterobacteriaceae. Mecillinam espe-
cially is active against Escherichia coli, Klebsi-
ella pneumoniae, Enterobacter species, Citro-
bacter species, Salmonella, and Shigella, but is
not active against Pseudomonas aeruginosa (5,
11). Mecillinam is relatively inactive against
gram-positive bacteria such as staphylococci and
streptococci (5, 6, 13). The activity ofmecillinam
against anaerobic bacteria has been tested on
only a limited basis (5, 10). The purpose of this
study was to further investigate the activity of
mecillinam against a wide range of anaerobic
bacteria.
MATERLALS AND METHODS
All anaerobic bacteria employed in this study were
recent clinical isolates recovered from wound, lower
respiratory, and genital tract specimens submitted to
the Clinical Microbiology Laboratories of the North
Carolina Memorial Hospital, Chapel Hill. All anaero-
bic bacteria employed for testing were first identified
through the use of gas-liquid chromatography and
specialized anaerobic biochemical tests (3). The fol-
lowing anaerobic bacteria were selected for study: 6
strains of Bacteroides corrodens, 15 B. melaninogen-
icus subsp. intermedius, 29 B. fragilis, 11 B. vulgatus,
15 B. distasonis, 7 B. ovatus, 22 B. thetaiotaomicron,
6 Clostridium tertium, 18 C. perfringens, 5 C. bifer-
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mentans, 5 C. innocuum, 9 Propionibacterium acnes,
6 Propionibacterium granulosum, 6 Peptococcus pre-
votii, 5 Peptococcus asaccharolyticus, 15 Peptostrep-
tococcus anaerobius, 6 Peptostreptococcus micros, 5
Eubacterium lentum, and 10 VeiloneUa parvula.
The in vitro activity of mecillinam against anerobic
bacteria was investigated by employing a microtiter
broth dilution method (8). By testing reference strains
of B. fragilis ATCC 25285 and C. perfringens ATCC
13124 against penicillin G, cefoxitin, and clindamycin,
this method was shown to yield results similar to those
obtained with the reference agar dilution method (9).
Mecillinam powder was supplied by Hoffmann-La
Roche, Inc., Nutley, N.J. The other antibiotic powders
were supplied as follows: penicillin G, Eli Lilly and
Co., Indianapolis, Ind.; cefoxitin, Merck Sharp and
Dohme, Inc., West Point, Pa.; and clindamycin, The
Upjohn Co., Kalamazoo, Mich. The mecillinam pow-
der initially was dissolved in sterile distilled water to
yield a concentration of 1,280 pg/ml. Twelve serial
twofold dilutions ranging between 128 and 0.06 pg/ml
were then prepared in sterile NIH broth supplemented
with 5 pug of hemin and 0.1 pug of menadione per ml.
NIH broth was prepared by dissolving 5 g of yeast
extract (Difco Laboratories, Detroit, Mich.), 15 g of
Trypticase-peptone (BBL Microbiology Systems,
Cockeysville, Md.), 1.0 g of dextrose, 2.5 g of sodium
chloride, and 0.05 g of L-cysteine in 1 liter of distilled
water. The medium was sterilized by autoclaving for
15 min at 121°C. The sterilized medium was then
supplemented with hemin and menadione to yield
final concentrations of 5 and 0.1 pg/ml, respectively.
The osmolality of the supplemented NIH broth was
determined to be 210 msmol/kg through use of an
Advanced Digimatic Osmoter, model 3D (Advanced
Instruments Co., Inc., Needham Heights, Mass.).
Portions (50 p1) of the mecillinam dilutions were
aseptically dispensed into sterile U-bottom microtiter
trays (Cooke Laboratories, Inc., Alexandria, Va.) with
a Dynatech MIC-2000 dispenser (Cooke Laboratories,
Inc.). Prepared microtiter trays not intended for use
within 24 h of preparation were sealed in polyethylene
bags and frozen at -70°C for a maximum of 2 weeks.
Microtiter plates were prepared for inoculation by first
incubating them at room temperature for 24 h in an
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anaerobic glove box (Coy Laboratory Products, Ann
Arbor, Mich.) containing an atmosphere of 85% nitro-
gen, 10% hydrogen, and 5% carbon dioxide.
The stability of mecillinam in the prepared micro-
titer trays was monitored by testing a strain of B.
fragilis (for which the minimal inhibitory concentra-
tion [MIC] of mecillinam was known) on each day
tests were performed. This quality control testing in-
dicated that the antibiotic was stable for at least 2
weeks under the storage, prereduction, and incubation
conditions employed. It also indicated that the anti-
biotic was not inactivated by the L-cysteine in the test
medium.
Organisms tested were first grown in the glove box
environment at 350C for 24 to 48 h on an agar medium
which consisted of the previously described NIH broth
supplemented with 1.5% agar and 5% defibrinated
sheep blood (Brown Laboratories, Topeka, Kans.).
Inocula were prepared by suspending well-isolated
colonies of each test strain from NIH blood agar plates
in 2 ml of supplemented Schaedler broth. The turbid-
ity of the organism suspension was adjusted to equal
that of a McFarland no. 0.5 turbidity standard. This
standardized suspension then was diluted 1:100 in
supplemented NIH broth. Volumes (50 pl) of the di-
luted suspension were added to each antibiotic-con-
taining well and to a growth control well containing 50
pl of supplemented broth without antibiotics. With
inoculation, the prepared antibiotic concentrations
were further diluted to yield concentrations of mecil-
linam that ranged between 64 and 0.03 ,ug/ml. Inocu-
lated plates were sealed in polyethylene bags and
incubated in a glove box at 35°C for 48 h. The incu-
bated plates were examined with an illuminated viewer
(Cooke Laboratories, Inc.), and the MIC was deter-
mined as the lowest concentration of antibiotic that
inhibited visible growth.
RESULTS
Table 1 presents the results obtained for the
201 strains of anaerobic bacteria tested. C. bifer-
mentans and E. lentum were the most suscep-
tible of the anaerobic gram-positive bacilli
tested. MICs for C. bifermentans ranged be-
tween 0.25 and 4.0 ,ug/ml, and MICs for E.
lentum ranged between 1.0 and 4.0 ,g/ml. More
elevated MICs were observed for P. acnes and
P. granulosum: between 2.0 and 16.0,ug/ml and
between 0.5 and 16,ug/ml, respectively. C. ter-
tium, C. innocuum, and C. perfringens were the
least susceptible of the anaerobic gram-positive
bacilli. MICs for C. perfringens ranged between
8.0 and 64 ,g/ml, whereas C. innocuum dis-
played MICs that ranged between 16 and 64 ,ug/
ml. C. tertium demonstrated MICs that ranged
between 8 and 32 ,ug/ml.
In comparison to the anaerobic gram-positive
bacilli, the anaerobic gram-negative bacilli dis-
played a wider range of MICs. B. corrodens and
B. vulgatus displayed MICs that ranged be-
tween 0.125 and 16.0 ,ug/ml. MICs for B. mela-
ninogenicus subsp. intermedius ranged between
0.125 and 16 ,ug/ml, and strains of B. distasonis
displayed MICs that ranged between -0.06 and
TABLE 1. In vitro activity of mecillinam against 201 strains of anaerobic bacteria
MIC (pg/mi)
Organism No. of strains For 90% of
Range For 50% of strams8 strains
Anaerobic gram-positive bacilli
Clostridium tertium 6 8-32 16 32
C. bifernentans 5 0.25-4 2 4
C. innocuum 5 16-64 16 64
C. perfringens 18 8-64 16 64
Propionibacterim acnes 9 2-16 4 8
P. granulosum 6 0.5-16 2 4
Eubacterium lentum 5 1-4 2 4
Anaerobic gram-negative bacilli
Bacteroides corrodens 6 0.125-16 0.5 16
B. melaninogenicussubsp. interme- 15 0.25-16 2 16
dius
B. fragilis 29 1-64 8 32
B. distasonis 15 0.06-16 1 16
B. thetaiotaomicron 22 4-64 8 32
B. vulgatus 11 0.125-16 0.5 8
B. ovatus 7 2-32 4 16
Anaerobic cocci
Peptostreptococcus anaerobius 15 0.125-16 2 8
P. micros 6 0.5-8 2 4
Peptococcus asaccharolyticus 5 0.5-8 2 8
P. prevotii 6 1-8 2 4
Veillonella parvula 10 0.5-4 1 2
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16 ,ug/ml. B. thetaiotaomicron and B. fragilis
were the most resistant of the anaerobic gram-
negative bacilli; each required 64 ,tg/ml for in-
hibition of all strains. A mecillinam concentra-
tion of 32 ,ug/ml was required for the inhibition
of all seven strains of B. ovatus tested.
V. parvula was the only anaerobic gram-neg-
ative coccus tested and displayed MICs ranging
between 0.5 and 4.0 ,ug/ml. Of the anaerobic
gram-positive cocci, all strains of P. micros, P.
prevotii, and P. asaccharolyticus demonstrated
MICs of s8.0 ,ug of mecillinam per ml. P. ana-
erobius displayed a wider range of MICs, with
values ranging between 0.125 and 16,g/ml. Ap-
proximately 93% of the P. anaerobius strains
were susceptible to 8.0 ,ug/ml, whereas approxi-
mately 7% required 16 ,tg/ml for inhibition.
DISCUSSION
Since mecillinam is poorly absorbed from the
gastrointestinal tract, effective oral therapy orig-
inally was not possible, and the antibiotic was
administered parenterally (7). Recently, an ef-
fective oral preparation has been developed.
Pivmecillinam, the pivaloyloxymethyl ester of
mecillinam, possesses no antibacterial activity
per se but is well absorbed from the gastrointes-
tinal tract. During or immediately after absorp-
tion, pivmecillinam is enzymatically hydrolyzed
to mecillinam (7).
Roholt and co-workers, in a study of 9 pa-
tients, found peak serum levels after intramus-
cular administration of either 250 or 500 mg of
mecillinam to be approximately 8 and 10lOg/ml,
respectively (7). The serum half-life of mecilli-
nam intramuscularly administered was approx-
imately 1 h (7). In a study of 10 fasting volun-
teers, Roholt and co-workers found mean peak
serum levels after the oral administration of 100
mg of pivmecillinam to be approximately 5 jig/
ml, with a serum half-life of approximately 1 h
(7).
Assuming a susceptible breakpoint for mecil-
linam to equal 4.0 jig/ml, this antibiotic appears
relatively inactive against anaerobic bacteria. B.
fragilis and C. perfringens, two of the most
commonly isolated anaerobic bacteria, are
highly resistant to mecillinam; none of the
strains of C. perfringens tested, and only about
34% of the strains ofB. fragilis, were susceptible
to c4.0 ,ug ofmecillinam per ml. C. bifermentans,
E. lentum, and V. parvula were the only anaer-
obic bacteria that demonstrated consistent sus-
ceptibility to mecillinam. Resistance among
other anaerobic bacteria was frequently encoun-
tered. Of all the anaerobic strains tested, for only
52.7% was the MIC <4.0,tg/ml. It is, therefore,
extremely difficult to predict susceptibility to
mecillinam. Since the susceptibility of the ma-
jority of anaerobic bacteria tested cannot be
predicted, susceptibility testing is mandatory if
mecillinam is ever to be considered for treatment
of anaerobic infections.
In vitro susceptibility testing of mecillinam
requires a medium with the proper osmolality
and conductivity. Susceptibility testing media
with high osmolality and conductivity have been
demonstrated to significantly reduce the activity
of mecillinam (1, 2, 12). The osmolahlity and
conductivity of the medium we employed were
sufficiently low to insure accurate measurements
of antibiotic activity.
Although mecillinam is active against many
aerobic gram-negative bacilli, its potential use
for the treatment ofanaerobic infections appears
limited. Should consideration be given to the
clinical use of mecillinam for the treatment of
anaerobic infections, in vitro susceptibility test-
ing is strongly indicated.
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